Alarming conditions and sleep disorder: modern principles of treatment

June 25, 2018
Specialities :

Generalized anxiety disorder (GAD) as alienation, characterized by a general steady alarm unconnected with certain objects or situations, to have a wide distribution has in a modern association. Clinically it is accompanied by proof sense of alarm no less than six months during most days. High prevalence of GAD is in a population, propensity to the protracted flow and high comorbidity with other psychonosemas, attended with in many cases the substantial worsening of ability to work and quality of life of patients, do a necessity the search of new effective facilities for treatment of this pathology. What and this article is devoted, where given it a shot to systematize present presently information on diagnostics and treatment of GAD and concomitant comorbidity states, in particular somnipathies.

Key words: the anxious states, alarm, comorbidity, generalized anxiety disorder, pregabalin, sleep, somnipathy, psychotherapy.

Published: 27.06.2018


  • Tvorogova N.D. (2007) Klinicheskaya psihologiya. PER SE, Moskva, 416 s.
  • Abler B., Hofer C., Walter H. et al. (2010) Habitual emotion regulation strategies and depressive symptoms in healthy subjects predict fMRI brain activation patterns related to major depression. Psychiatry Res., 183(2): 105–113.
  • Acet G., Kaya A., Akturk S., Akgol G. (2017) A comparison of the effectiveness of amitriptilin and pregabalin treatment in fibromyalgia patients. North Clin. Istanb., 4(2): 151–159.
  • Baldwin D., Woods R., Lawson R., Taylor D. (2011) Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ, 342: d1199.
  • Baldwin D.S., Loft H., Dragheim M. (2012) A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur. Neuropsychopharmacol., 22(7): 482–489.
  • Bandelow B., Michaelis S. (2015) Epidemiology of anxiety disorders in the 21st century. Dialog. Clin. Neurosci, 17(3): 327–335.
  • Bech P. (2007) Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebocontrolled trials. Pharmacopsychiatry, 40: 163–168.
  • Cape J., Whittington C., Buszewicz M. et al. (2010) Brief psychological therapies for anxiety and depression in primary care: meta-analysis and meta — regression. BMC Med., 8: 38.
  • Dement W. (1960) The effect of dream deprivation. Science, 131(3415): 1705–1707.
  • Den Boer J., Westenberg H., Kamerbeek W. et al. (1987) Effect of serotonin uptake inhibitors in anxiety disorders. Int. Clin. Psychiat., 2(2): 21–32.
  • Etkin A., Wager T.D. (2007) Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am. J. Psychiatry, 164(10): 1476–1488.
  • Feltner D., Wittchen H.U., Kavoussi R. et al. (2008) Long-term efficacy of pregabalin in generalized anxiety disorder. Int. Clin. Psychopharmacol., 23: 18–28.
  • Gorman J.M. (2002) Treatment of Generalized Anxiety Disorder. J. Clin. Psychiatry, 63(suppl 8): 17–23.
  • Grossman P., Niemann L., Schmidt S., Walach H. (2004) Mindfulness-based stress reduction and health benefits: a meta-analysis. J. Psychosom. Res., 57(1) :35–43.
  • Guaiana G., Barbui C., Cipriani A. (2010) Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst. Rev., Dec. 8(12).
  • Jacobi F., Hofler M., Strehle J. et al. (2014) Mental disorders in the general population: study on the health of adults in Germany and the additional module mental health (DEGS1-MH) [in German]. Nervenarzt., 85(1): 77–87.
  • Kessler R.C., Demler O., Frank R.G. et al. (2005) Prevalence and treatment of mental disorders, 1990 to 2003. N. Engl. J. Med., 352(24): 2515–2523.
  • Lee H.B., Song M.L., Koo B.B., Cho Y.W. (2017) Mood symptoms and restless legs syndrome without periodic limb movements during sleep: is it a clinical subtype? J. Neuropsychiatry Clin. Neurosci, 29(1): 52–59.
  • Lichstein K.L., Taylor D.J., McCrae C.S. et al. (2016) Insomnia: epidemiology and risk factors. In: Principles and practice of sleep medicine. Е by M.H. Kryger, T. Roth, W.C. Dement. 6th ed. Elsevier, Philadelphia, р. 761–768.
  • Locke A.B., Kirst N., Shultz C.G. (2015) Diagnosis and management of generalized anxiety disorder and panic disorder in adults. Am. Fam. Physician., 91(9): 617–624.
  • Lydiard R.B., Rickels K., Herman B., Feltner D.E. (2010) Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int. J. Neuropsychopharmacol., 13(2): 229–241.
  • Mason E.C., Harvey A.G. (2014) Insomnia before and after treatment for anxiety and depression. J. Affect. Disord., 168: 415–421.
  • Meibach R.C., Dunner D., Wilson L.G. et al. (1987) Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. J. Clin. Psychiatry, 48(9): 355–358.
  • Montgomery S.A., Baldwin D.S., Blier P. et al. (2007) Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int. Psychopharmacol., 22(6): 323–329.
  • Montgomery S.A., Nil R. et al. (2005) A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J. Clin. Psychiatry, 66: 1270–1278.
  • National Institute for Health and Care Excellence (NICE) (2011) Genera­lised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care. Jan. 2011.
  • Pande A.C., Crockatt J.G., Feltner D.E. et al. (2003) Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am. J. Psychiatry, 160: 533–540.
  • Papazisis G., Tzachanis D. (2014) Pregabalin’s abuse potential: a mini review focusing on the pharmacological profile. Int. J. Clin. Pharmacol. Therap., 52: 709–716.
  • Paulesu E., Sambugaro E., Torti T. et al. (2010) Neural correlates of worry in generalized anxiety disorder and in normal controls: a functional MRI study. Psychol. Med., 40(1): 117–124.
  • Pélissolo A., André C., Chignon J.M. et al. (2002) Anxiety disorders in private practice psychiatric out-patients: prevalence, comorbidity and burden (DELTA study). Encephale, 28(6 Pt. 1): 510–519.
  • Regier D.A., Kuhl E.A., Kupfer D.J. (2013) The DSM-5: Classification and criteria changes. World Psychiatry, 12(2): 92–98.
  • Rouillon Е., Chignon J.М. (1992) Psychiatric comorbidity of anxiety disorders in the year 2000: Controversies and perspectives. — Proceedings of the meeting held in Paris 9, June 1992. J. A. Costa-a-Silva (Ed.), p. 26–34.
  • Spitzer R.L., Kroenke K., Williams J.B., Löwe B. (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch. Intern. Med., 166(10): 1092–1097.
  • Taguchi T., Igarashi A., Watt S. et al. (2015) Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study in Japan. J. Pain Res., 8: 487–497.
  • Taylor D.J., Mallory L.J., Lichstein K.L. et al. (2007) Comorbidity of chronic insomnia with medical problems. Sleep, 30(2): 213−218.
  • The Diagnostic and Statistical Manual of Mental Disorders, fifth edition: DSM 5 (2013) American Psychiatric Association. American Psychiatric Publishing, Washington, DC.
  • Wensel T.M., Powe K.W., Cates M.E. (2012) Pregabalin for the Treatment of Generalized Anxiety Disorder. Ann. Pharmacother., 46: 424–429.